nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—EBP—Tamoxifen—pancreatic cancer	0.229	0.297	CbGbCtD
Raloxifene—ESR2—Tamoxifen—pancreatic cancer	0.155	0.201	CbGbCtD
Raloxifene—SIGMAR1—Tamoxifen—pancreatic cancer	0.0984	0.128	CbGbCtD
Raloxifene—ESR1—Tamoxifen—pancreatic cancer	0.0796	0.103	CbGbCtD
Raloxifene—CYP19A1—Tamoxifen—pancreatic cancer	0.0645	0.0837	CbGbCtD
Raloxifene—CYP2B6—Tamoxifen—pancreatic cancer	0.0266	0.0345	CbGbCtD
Raloxifene—CYP2B6—Irinotecan—pancreatic cancer	0.0204	0.0265	CbGbCtD
Raloxifene—CYP2C8—Tamoxifen—pancreatic cancer	0.0202	0.0261	CbGbCtD
Raloxifene—CYP2C8—Erlotinib—pancreatic cancer	0.0171	0.0222	CbGbCtD
Raloxifene—CYP2C8—Fluorouracil—pancreatic cancer	0.0149	0.0193	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—pancreatic cancer	0.0112	0.0145	CbGbCtD
Raloxifene—CYP3A4—Tamoxifen—pancreatic cancer	0.00817	0.0106	CbGbCtD
Raloxifene—CYP3A4—Erlotinib—pancreatic cancer	0.00695	0.00901	CbGbCtD
Raloxifene—CYP3A4—Irinotecan—pancreatic cancer	0.00628	0.00814	CbGbCtD
Raloxifene—CYP3A4—Docetaxel—pancreatic cancer	0.0046	0.00596	CbGbCtD
Raloxifene—CYP3A4—Sunitinib—pancreatic cancer	0.00458	0.00594	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—pancreatic cancer	0.00343	0.00445	CbGbCtD
Raloxifene—EBP—Azacitidine—Gemcitabine—pancreatic cancer	0.00144	1	CbGdCrCtD
Raloxifene—Vaginal infection—Doxorubicin—pancreatic cancer	0.000278	0.00175	CcSEcCtD
Raloxifene—Abdominal pain—Tamoxifen—pancreatic cancer	0.000273	0.00171	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—pancreatic cancer	0.00027	0.0017	CcSEcCtD
Raloxifene—Abdominal pain—Erlotinib—pancreatic cancer	0.00027	0.0017	CcSEcCtD
Raloxifene—Body temperature increased—Erlotinib—pancreatic cancer	0.00027	0.0017	CcSEcCtD
Raloxifene—Weight increased—Docetaxel—pancreatic cancer	0.000269	0.00169	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000269	0.00169	CcSEcCtD
Raloxifene—Vertigo—Irinotecan—pancreatic cancer	0.000268	0.00168	CcSEcCtD
Raloxifene—Syncope—Irinotecan—pancreatic cancer	0.000267	0.00168	CcSEcCtD
Raloxifene—Insomnia—Sunitinib—pancreatic cancer	0.000267	0.00168	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—pancreatic cancer	0.000266	0.00167	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—pancreatic cancer	0.000265	0.00167	CcSEcCtD
Raloxifene—Pneumonia—Docetaxel—pancreatic cancer	0.000265	0.00167	CcSEcCtD
Raloxifene—Loss of consciousness—Irinotecan—pancreatic cancer	0.000262	0.00165	CcSEcCtD
Raloxifene—Cough—Irinotecan—pancreatic cancer	0.00026	0.00163	CcSEcCtD
Raloxifene—Dyspepsia—Sunitinib—pancreatic cancer	0.00026	0.00163	CcSEcCtD
Raloxifene—Conjunctivitis—Docetaxel—pancreatic cancer	0.000256	0.00161	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000255	0.0016	CcSEcCtD
Raloxifene—Cough—Gemcitabine—pancreatic cancer	0.000253	0.00159	CcSEcCtD
Raloxifene—Pain—Sunitinib—pancreatic cancer	0.000252	0.00159	CcSEcCtD
Raloxifene—Myalgia—Gemcitabine—pancreatic cancer	0.000247	0.00155	CcSEcCtD
Raloxifene—Arthralgia—Gemcitabine—pancreatic cancer	0.000247	0.00155	CcSEcCtD
Raloxifene—Chest pain—Gemcitabine—pancreatic cancer	0.000247	0.00155	CcSEcCtD
Raloxifene—Hot flush—Epirubicin—pancreatic cancer	0.000247	0.00155	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.000245	0.00154	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000245	0.00154	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—pancreatic cancer	0.000245	0.00154	CcSEcCtD
Raloxifene—Chest pain—Fluorouracil—pancreatic cancer	0.000243	0.00153	CcSEcCtD
Raloxifene—Myalgia—Fluorouracil—pancreatic cancer	0.000243	0.00153	CcSEcCtD
Raloxifene—Infection—Irinotecan—pancreatic cancer	0.000242	0.00152	CcSEcCtD
Raloxifene—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000241	0.00152	CcSEcCtD
Raloxifene—Shock—Irinotecan—pancreatic cancer	0.000239	0.0015	CcSEcCtD
Raloxifene—Nervous system disorder—Irinotecan—pancreatic cancer	0.000239	0.0015	CcSEcCtD
Raloxifene—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000238	0.0015	CcSEcCtD
Raloxifene—Rhinitis—Docetaxel—pancreatic cancer	0.000237	0.00149	CcSEcCtD
Raloxifene—Diarrhoea—Tamoxifen—pancreatic cancer	0.000236	0.00148	CcSEcCtD
Raloxifene—Hypoaesthesia—Docetaxel—pancreatic cancer	0.000235	0.00148	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.000235	0.00148	CcSEcCtD
Raloxifene—Infection—Gemcitabine—pancreatic cancer	0.000235	0.00148	CcSEcCtD
Raloxifene—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000235	0.00148	CcSEcCtD
Raloxifene—Pharyngitis—Docetaxel—pancreatic cancer	0.000235	0.00148	CcSEcCtD
Raloxifene—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000234	0.00147	CcSEcCtD
Raloxifene—Abdominal pain—Sunitinib—pancreatic cancer	0.000233	0.00147	CcSEcCtD
Raloxifene—Body temperature increased—Sunitinib—pancreatic cancer	0.000233	0.00147	CcSEcCtD
Raloxifene—Diarrhoea—Erlotinib—pancreatic cancer	0.000233	0.00147	CcSEcCtD
Raloxifene—Oedema peripheral—Docetaxel—pancreatic cancer	0.000233	0.00147	CcSEcCtD
Raloxifene—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000233	0.00146	CcSEcCtD
Raloxifene—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000232	0.00146	CcSEcCtD
Raloxifene—Urethral disorder—Docetaxel—pancreatic cancer	0.000232	0.00146	CcSEcCtD
Raloxifene—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000232	0.00146	CcSEcCtD
Raloxifene—Infection—Fluorouracil—pancreatic cancer	0.000231	0.00145	CcSEcCtD
Raloxifene—Skin disorder—Gemcitabine—pancreatic cancer	0.00023	0.00145	CcSEcCtD
Raloxifene—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000229	0.00144	CcSEcCtD
Raloxifene—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000228	0.00144	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—pancreatic cancer	0.000228	0.00143	CcSEcCtD
Raloxifene—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000228	0.00143	CcSEcCtD
Raloxifene—Dizziness—Tamoxifen—pancreatic cancer	0.000228	0.00143	CcSEcCtD
Raloxifene—Migraine—Epirubicin—pancreatic cancer	0.000227	0.00143	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—pancreatic cancer	0.000226	0.00142	CcSEcCtD
Raloxifene—Dizziness—Erlotinib—pancreatic cancer	0.000226	0.00142	CcSEcCtD
Raloxifene—Insomnia—Irinotecan—pancreatic cancer	0.00022	0.00138	CcSEcCtD
Raloxifene—Flushing—Docetaxel—pancreatic cancer	0.00022	0.00138	CcSEcCtD
Raloxifene—Cardiac disorder—Docetaxel—pancreatic cancer	0.00022	0.00138	CcSEcCtD
Raloxifene—Vomiting—Tamoxifen—pancreatic cancer	0.000219	0.00138	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000218	0.00137	CcSEcCtD
Raloxifene—Rash—Tamoxifen—pancreatic cancer	0.000217	0.00137	CcSEcCtD
Raloxifene—Dermatitis—Tamoxifen—pancreatic cancer	0.000217	0.00137	CcSEcCtD
Raloxifene—Vomiting—Erlotinib—pancreatic cancer	0.000217	0.00136	CcSEcCtD
Raloxifene—Headache—Tamoxifen—pancreatic cancer	0.000216	0.00136	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000216	0.00136	CcSEcCtD
Raloxifene—Rash—Erlotinib—pancreatic cancer	0.000215	0.00135	CcSEcCtD
Raloxifene—Dermatitis—Erlotinib—pancreatic cancer	0.000215	0.00135	CcSEcCtD
Raloxifene—Angiopathy—Docetaxel—pancreatic cancer	0.000215	0.00135	CcSEcCtD
Raloxifene—Insomnia—Gemcitabine—pancreatic cancer	0.000214	0.00135	CcSEcCtD
Raloxifene—Dyspepsia—Irinotecan—pancreatic cancer	0.000214	0.00135	CcSEcCtD
Raloxifene—Headache—Erlotinib—pancreatic cancer	0.000214	0.00134	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000212	0.00133	CcSEcCtD
Raloxifene—Insomnia—Fluorouracil—pancreatic cancer	0.000211	0.00132	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—pancreatic cancer	0.00021	0.00132	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00021	0.00132	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—pancreatic cancer	0.000208	0.00131	CcSEcCtD
Raloxifene—Pain—Irinotecan—pancreatic cancer	0.000208	0.00131	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000208	0.00131	CcSEcCtD
Raloxifene—Dyspepsia—Fluorouracil—pancreatic cancer	0.000205	0.00129	CcSEcCtD
Raloxifene—Nausea—Tamoxifen—pancreatic cancer	0.000205	0.00129	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000205	0.00129	CcSEcCtD
Raloxifene—Pain—Gemcitabine—pancreatic cancer	0.000203	0.00127	CcSEcCtD
Raloxifene—Nausea—Erlotinib—pancreatic cancer	0.000203	0.00127	CcSEcCtD
Raloxifene—Diarrhoea—Sunitinib—pancreatic cancer	0.000202	0.00127	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000201	0.00126	CcSEcCtD
Raloxifene—Influenza—Epirubicin—pancreatic cancer	0.000199	0.00125	CcSEcCtD
Raloxifene—Pain—Fluorouracil—pancreatic cancer	0.000199	0.00125	CcSEcCtD
Raloxifene—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000199	0.00125	CcSEcCtD
Raloxifene—Muscle spasms—Docetaxel—pancreatic cancer	0.000198	0.00125	CcSEcCtD
Raloxifene—Dizziness—Sunitinib—pancreatic cancer	0.000195	0.00123	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—pancreatic cancer	0.000193	0.00121	CcSEcCtD
Raloxifene—Body temperature increased—Irinotecan—pancreatic cancer	0.000192	0.00121	CcSEcCtD
Raloxifene—Abdominal pain—Irinotecan—pancreatic cancer	0.000192	0.00121	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000192	0.00121	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—pancreatic cancer	0.000192	0.00121	CcSEcCtD
Raloxifene—Vomiting—Sunitinib—pancreatic cancer	0.000188	0.00118	CcSEcCtD
Raloxifene—Body temperature increased—Gemcitabine—pancreatic cancer	0.000187	0.00118	CcSEcCtD
Raloxifene—Rash—Sunitinib—pancreatic cancer	0.000186	0.00117	CcSEcCtD
Raloxifene—Dermatitis—Sunitinib—pancreatic cancer	0.000186	0.00117	CcSEcCtD
Raloxifene—Headache—Sunitinib—pancreatic cancer	0.000185	0.00116	CcSEcCtD
Raloxifene—Syncope—Docetaxel—pancreatic cancer	0.000185	0.00116	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—pancreatic cancer	0.000185	0.00116	CcSEcCtD
Raloxifene—Body temperature increased—Fluorouracil—pancreatic cancer	0.000184	0.00116	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—pancreatic cancer	0.000181	0.00114	CcSEcCtD
Raloxifene—Loss of consciousness—Docetaxel—pancreatic cancer	0.000181	0.00114	CcSEcCtD
Raloxifene—Cough—Docetaxel—pancreatic cancer	0.00018	0.00113	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—pancreatic cancer	0.000179	0.00112	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—pancreatic cancer	0.000177	0.00112	CcSEcCtD
Raloxifene—Myalgia—Docetaxel—pancreatic cancer	0.000175	0.0011	CcSEcCtD
Raloxifene—Arthralgia—Docetaxel—pancreatic cancer	0.000175	0.0011	CcSEcCtD
Raloxifene—Chest pain—Docetaxel—pancreatic cancer	0.000175	0.0011	CcSEcCtD
Raloxifene—Nausea—Sunitinib—pancreatic cancer	0.000175	0.0011	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000174	0.00109	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—pancreatic cancer	0.000173	0.00109	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—pancreatic cancer	0.000173	0.00109	CcSEcCtD
Raloxifene—Sweating—Epirubicin—pancreatic cancer	0.00017	0.00107	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—pancreatic cancer	0.000168	0.00106	CcSEcCtD
Raloxifene—Infection—Docetaxel—pancreatic cancer	0.000167	0.00105	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—pancreatic cancer	0.000167	0.00105	CcSEcCtD
Raloxifene—Diarrhoea—Irinotecan—pancreatic cancer	0.000166	0.00105	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—pancreatic cancer	0.000165	0.00104	CcSEcCtD
Raloxifene—Shock—Docetaxel—pancreatic cancer	0.000165	0.00104	CcSEcCtD
Raloxifene—Nervous system disorder—Docetaxel—pancreatic cancer	0.000165	0.00104	CcSEcCtD
Raloxifene—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000165	0.00103	CcSEcCtD
Raloxifene—Skin disorder—Docetaxel—pancreatic cancer	0.000163	0.00103	CcSEcCtD
Raloxifene—Diarrhoea—Gemcitabine—pancreatic cancer	0.000162	0.00102	CcSEcCtD
Raloxifene—Dizziness—Irinotecan—pancreatic cancer	0.000161	0.00101	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—pancreatic cancer	0.00016	0.00101	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—pancreatic cancer	0.00016	0.00101	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00016	0.00101	CcSEcCtD
Raloxifene—Diarrhoea—Fluorouracil—pancreatic cancer	0.000159	0.001	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000159	0.000998	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—pancreatic cancer	0.000158	0.000996	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—pancreatic cancer	0.000158	0.000992	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000158	0.000991	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—pancreatic cancer	0.000157	0.000988	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000157	0.000986	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—pancreatic cancer	0.000156	0.000984	CcSEcCtD
Raloxifene—Vomiting—Irinotecan—pancreatic cancer	0.000155	0.000972	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—pancreatic cancer	0.000154	0.00097	CcSEcCtD
Raloxifene—Dizziness—Fluorouracil—pancreatic cancer	0.000154	0.000968	CcSEcCtD
Raloxifene—Rash—Irinotecan—pancreatic cancer	0.000153	0.000964	CcSEcCtD
Raloxifene—Dermatitis—Irinotecan—pancreatic cancer	0.000153	0.000963	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000153	0.000963	CcSEcCtD
Raloxifene—Headache—Irinotecan—pancreatic cancer	0.000152	0.000958	CcSEcCtD
Raloxifene—Insomnia—Docetaxel—pancreatic cancer	0.000152	0.000956	CcSEcCtD
Raloxifene—Vomiting—Gemcitabine—pancreatic cancer	0.000151	0.000947	CcSEcCtD
Raloxifene—Rash—Gemcitabine—pancreatic cancer	0.000149	0.000939	CcSEcCtD
Raloxifene—Dermatitis—Gemcitabine—pancreatic cancer	0.000149	0.000938	CcSEcCtD
Raloxifene—Headache—Gemcitabine—pancreatic cancer	0.000148	0.000933	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—pancreatic cancer	0.000148	0.000931	CcSEcCtD
Raloxifene—Flushing—Epirubicin—pancreatic cancer	0.000148	0.000931	CcSEcCtD
Raloxifene—Vomiting—Fluorouracil—pancreatic cancer	0.000148	0.000931	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—pancreatic cancer	0.000148	0.000931	CcSEcCtD
Raloxifene—Dyspepsia—Docetaxel—pancreatic cancer	0.000148	0.00093	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000147	0.000924	CcSEcCtD
Raloxifene—Rash—Fluorouracil—pancreatic cancer	0.000147	0.000923	CcSEcCtD
Raloxifene—Dermatitis—Fluorouracil—pancreatic cancer	0.000147	0.000922	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—pancreatic cancer	0.000147	0.000921	CcSEcCtD
Raloxifene—Headache—Fluorouracil—pancreatic cancer	0.000146	0.000917	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000146	0.000917	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000145	0.000915	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000145	0.000912	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000145	0.000912	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—pancreatic cancer	0.000145	0.00091	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—pancreatic cancer	0.000145	0.00091	CcSEcCtD
Raloxifene—Nausea—Irinotecan—pancreatic cancer	0.000144	0.000908	CcSEcCtD
Raloxifene—Pain—Docetaxel—pancreatic cancer	0.000144	0.000904	CcSEcCtD
Raloxifene—Nausea—Gemcitabine—pancreatic cancer	0.000141	0.000885	CcSEcCtD
Raloxifene—Nausea—Fluorouracil—pancreatic cancer	0.000138	0.00087	CcSEcCtD
Raloxifene—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000137	0.000864	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—pancreatic cancer	0.000137	0.000862	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000137	0.000862	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—pancreatic cancer	0.000137	0.000861	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—pancreatic cancer	0.000134	0.000842	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—pancreatic cancer	0.000134	0.00084	CcSEcCtD
Raloxifene—Body temperature increased—Docetaxel—pancreatic cancer	0.000133	0.000836	CcSEcCtD
Raloxifene—Abdominal pain—Docetaxel—pancreatic cancer	0.000133	0.000836	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—pancreatic cancer	0.000127	0.000796	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—pancreatic cancer	0.000125	0.000785	CcSEcCtD
Raloxifene—Syncope—Epirubicin—pancreatic cancer	0.000125	0.000783	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—pancreatic cancer	0.000124	0.000777	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—pancreatic cancer	0.000122	0.000768	CcSEcCtD
Raloxifene—Cough—Epirubicin—pancreatic cancer	0.000121	0.000762	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—pancreatic cancer	0.000118	0.000744	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—pancreatic cancer	0.000118	0.000744	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—pancreatic cancer	0.000118	0.000744	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000117	0.000739	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—pancreatic cancer	0.000116	0.000726	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—pancreatic cancer	0.000115	0.000725	CcSEcCtD
Raloxifene—Diarrhoea—Docetaxel—pancreatic cancer	0.000115	0.000723	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000113	0.00071	CcSEcCtD
Raloxifene—Infection—Epirubicin—pancreatic cancer	0.000113	0.000708	CcSEcCtD
Raloxifene—Cough—Doxorubicin—pancreatic cancer	0.000112	0.000705	CcSEcCtD
Raloxifene—Shock—Epirubicin—pancreatic cancer	0.000112	0.000701	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—pancreatic cancer	0.000111	0.000699	CcSEcCtD
Raloxifene—Dizziness—Docetaxel—pancreatic cancer	0.000111	0.000699	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000111	0.000698	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—pancreatic cancer	0.00011	0.000692	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00011	0.000689	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—pancreatic cancer	0.000109	0.000688	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—pancreatic cancer	0.000109	0.000688	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—pancreatic cancer	0.000109	0.000688	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000109	0.000683	CcSEcCtD
Raloxifene—Vomiting—Docetaxel—pancreatic cancer	0.000107	0.000672	CcSEcCtD
Raloxifene—Rash—Docetaxel—pancreatic cancer	0.000106	0.000666	CcSEcCtD
Raloxifene—Dermatitis—Docetaxel—pancreatic cancer	0.000106	0.000666	CcSEcCtD
Raloxifene—Headache—Docetaxel—pancreatic cancer	0.000105	0.000662	CcSEcCtD
Raloxifene—Infection—Doxorubicin—pancreatic cancer	0.000104	0.000655	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000103	0.00065	CcSEcCtD
Raloxifene—Shock—Doxorubicin—pancreatic cancer	0.000103	0.000649	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000103	0.000647	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000103	0.000646	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—pancreatic cancer	0.000103	0.000645	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—pancreatic cancer	0.000102	0.000641	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000101	0.000638	CcSEcCtD
Raloxifene—Nausea—Docetaxel—pancreatic cancer	9.99e-05	0.000628	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—pancreatic cancer	9.98e-05	0.000628	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.79e-05	0.000615	CcSEcCtD
Raloxifene—Pain—Epirubicin—pancreatic cancer	9.7e-05	0.00061	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.56e-05	0.000601	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—pancreatic cancer	9.49e-05	0.000597	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.27e-05	0.000583	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—pancreatic cancer	9.24e-05	0.000581	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	9.06e-05	0.000569	CcSEcCtD
Raloxifene—Pain—Doxorubicin—pancreatic cancer	8.97e-05	0.000564	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—pancreatic cancer	8.96e-05	0.000564	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—pancreatic cancer	8.96e-05	0.000564	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.58e-05	0.000539	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—pancreatic cancer	8.29e-05	0.000521	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—pancreatic cancer	8.29e-05	0.000521	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—pancreatic cancer	7.76e-05	0.000488	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—pancreatic cancer	7.5e-05	0.000471	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—pancreatic cancer	7.21e-05	0.000453	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—pancreatic cancer	7.18e-05	0.000451	CcSEcCtD
Raloxifene—Rash—Epirubicin—pancreatic cancer	7.15e-05	0.000449	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—pancreatic cancer	7.14e-05	0.000449	CcSEcCtD
Raloxifene—Headache—Epirubicin—pancreatic cancer	7.1e-05	0.000447	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—pancreatic cancer	6.94e-05	0.000436	CcSEcCtD
Raloxifene—Nausea—Epirubicin—pancreatic cancer	6.74e-05	0.000423	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—pancreatic cancer	6.67e-05	0.000419	CcSEcCtD
Raloxifene—Rash—Doxorubicin—pancreatic cancer	6.62e-05	0.000416	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—pancreatic cancer	6.61e-05	0.000416	CcSEcCtD
Raloxifene—Headache—Doxorubicin—pancreatic cancer	6.57e-05	0.000413	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—pancreatic cancer	6.23e-05	0.000392	CcSEcCtD
Raloxifene—ESR1—Signaling Pathways—MEN1—pancreatic cancer	1.98e-05	0.00029	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.98e-05	0.00029	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CD—pancreatic cancer	1.97e-05	0.000289	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SST—pancreatic cancer	1.97e-05	0.000288	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GCG—pancreatic cancer	1.95e-05	0.000286	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CG—pancreatic cancer	1.94e-05	0.000284	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CG—pancreatic cancer	1.93e-05	0.000283	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JAG1—pancreatic cancer	1.93e-05	0.000282	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GCG—pancreatic cancer	1.92e-05	0.000282	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH3—pancreatic cancer	1.92e-05	0.000281	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMP—pancreatic cancer	1.9e-05	0.000278	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SHH—pancreatic cancer	1.89e-05	0.000277	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PIK3CA—pancreatic cancer	1.89e-05	0.000277	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH4—pancreatic cancer	1.88e-05	0.000275	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.87e-05	0.000274	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IAPP—pancreatic cancer	1.87e-05	0.000274	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—SMAD4—pancreatic cancer	1.85e-05	0.000271	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—STK11—pancreatic cancer	1.84e-05	0.000269	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AGTR1—pancreatic cancer	1.83e-05	0.000269	CbGpPWpGaD
Raloxifene—AOX1—Disease—CTNNB1—pancreatic cancer	1.82e-05	0.000266	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CNR1—pancreatic cancer	1.82e-05	0.000266	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GLP1R—pancreatic cancer	1.81e-05	0.000265	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STK11—pancreatic cancer	1.81e-05	0.000265	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTCH1—pancreatic cancer	1.79e-05	0.000263	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTHLH—pancreatic cancer	1.79e-05	0.000263	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—DPYD—pancreatic cancer	1.78e-05	0.000261	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTEN—pancreatic cancer	1.77e-05	0.00026	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CG—pancreatic cancer	1.76e-05	0.000258	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GCG—pancreatic cancer	1.75e-05	0.000257	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.72e-05	0.000252	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CB—pancreatic cancer	1.72e-05	0.000252	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.71e-05	0.00025	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—pancreatic cancer	1.7e-05	0.000249	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CD—pancreatic cancer	1.7e-05	0.000249	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC2A2—pancreatic cancer	1.69e-05	0.000247	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AGTR1—pancreatic cancer	1.67e-05	0.000245	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STK11—pancreatic cancer	1.65e-05	0.000242	CbGpPWpGaD
Raloxifene—AOX1—Disease—SRC—pancreatic cancer	1.64e-05	0.000241	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SST—pancreatic cancer	1.64e-05	0.00024	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.63e-05	0.000239	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JAG1—pancreatic cancer	1.6e-05	0.000235	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH3—pancreatic cancer	1.6e-05	0.000234	CbGpPWpGaD
Raloxifene—AOX1—Disease—STAT3—pancreatic cancer	1.58e-05	0.000232	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SMAD4—pancreatic cancer	1.58e-05	0.000232	CbGpPWpGaD
Raloxifene—AOX1—Disease—NRAS—pancreatic cancer	1.58e-05	0.000232	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TYMS—pancreatic cancer	1.58e-05	0.000231	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.57e-05	0.00023	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL8—pancreatic cancer	1.57e-05	0.000229	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CD—pancreatic cancer	1.55e-05	0.000227	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HES1—pancreatic cancer	1.55e-05	0.000226	CbGpPWpGaD
Raloxifene—EBP—Metabolism—AKT1—pancreatic cancer	1.54e-05	0.000226	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GLP1R—pancreatic cancer	1.53e-05	0.000224	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MYC—pancreatic cancer	1.52e-05	0.000223	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CNR1—pancreatic cancer	1.51e-05	0.000222	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—DPYD—pancreatic cancer	1.51e-05	0.000221	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.49e-05	0.000218	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTEN—pancreatic cancer	1.48e-05	0.000217	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CB—pancreatic cancer	1.48e-05	0.000217	CbGpPWpGaD
Raloxifene—AOX1—Disease—MYC—pancreatic cancer	1.47e-05	0.000216	CbGpPWpGaD
Raloxifene—AOX1—Disease—TGFB1—pancreatic cancer	1.47e-05	0.000215	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GCG—pancreatic cancer	1.46e-05	0.000214	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MYC—pancreatic cancer	1.46e-05	0.000213	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SMAD4—pancreatic cancer	1.44e-05	0.000212	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—pancreatic cancer	1.44e-05	0.000211	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	1.43e-05	0.000209	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL8—pancreatic cancer	1.43e-05	0.000209	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL8—pancreatic cancer	1.42e-05	0.000208	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.41e-05	0.000207	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HES1—pancreatic cancer	1.41e-05	0.000207	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AGTR1—pancreatic cancer	1.39e-05	0.000204	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STK11—pancreatic cancer	1.37e-05	0.000201	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.37e-05	0.0002	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NOTCH1—pancreatic cancer	1.36e-05	0.0002	CbGpPWpGaD
Raloxifene—AOX1—Disease—KRAS—pancreatic cancer	1.36e-05	0.000199	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TERT—pancreatic cancer	1.35e-05	0.000198	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CB—pancreatic cancer	1.35e-05	0.000198	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.35e-05	0.000197	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CD44—pancreatic cancer	1.31e-05	0.000192	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—pancreatic cancer	1.3e-05	0.00019	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HIF1A—pancreatic cancer	1.3e-05	0.00019	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TSC2—pancreatic cancer	1.29e-05	0.000189	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARG—pancreatic cancer	1.29e-05	0.000189	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—APOE—pancreatic cancer	1.28e-05	0.000188	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APOE—pancreatic cancer	1.26e-05	0.000185	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GCG—pancreatic cancer	1.25e-05	0.000184	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CA—pancreatic cancer	1.25e-05	0.000183	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.24e-05	0.000182	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KDR—pancreatic cancer	1.24e-05	0.000181	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TERT—pancreatic cancer	1.24e-05	0.000181	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.22e-05	0.000178	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SMAD4—pancreatic cancer	1.2e-05	0.000176	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HIF1A—pancreatic cancer	1.18e-05	0.000173	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TSC2—pancreatic cancer	1.18e-05	0.000173	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—STK11—pancreatic cancer	1.18e-05	0.000173	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NFKBIA—pancreatic cancer	1.18e-05	0.000173	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HES1—pancreatic cancer	1.18e-05	0.000172	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH1—pancreatic cancer	1.17e-05	0.000171	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.17e-05	0.000171	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CG—pancreatic cancer	1.16e-05	0.00017	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—pancreatic cancer	1.16e-05	0.000169	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOE—pancreatic cancer	1.15e-05	0.000169	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CG—pancreatic cancer	1.14e-05	0.000167	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—NRAS—pancreatic cancer	1.14e-05	0.000167	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KDR—pancreatic cancer	1.13e-05	0.000166	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGF—pancreatic cancer	1.13e-05	0.000165	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARG—pancreatic cancer	1.12e-05	0.000164	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CD44—pancreatic cancer	1.11e-05	0.000162	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.08e-05	0.000159	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NFKBIA—pancreatic cancer	1.08e-05	0.000158	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.07e-05	0.000157	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH1—pancreatic cancer	1.06e-05	0.000156	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GCG—pancreatic cancer	1.06e-05	0.000156	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—pancreatic cancer	1.05e-05	0.000153	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—pancreatic cancer	1.04e-05	0.000153	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—pancreatic cancer	1.04e-05	0.000153	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—pancreatic cancer	1.04e-05	0.000152	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—pancreatic cancer	1.03e-05	0.000151	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGF—pancreatic cancer	1.03e-05	0.000151	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—pancreatic cancer	1.02e-05	0.00015	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.02e-05	0.000149	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CD—pancreatic cancer	1.02e-05	0.000149	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMS—pancreatic cancer	1.01e-05	0.000149	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—pancreatic cancer	1.01e-05	0.000148	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CD—pancreatic cancer	1e-05	0.000147	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—STK11—pancreatic cancer	9.98e-06	0.000146	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—pancreatic cancer	9.93e-06	0.000146	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—pancreatic cancer	9.85e-06	0.000144	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TSC2—pancreatic cancer	9.82e-06	0.000144	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—pancreatic cancer	9.82e-06	0.000144	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOE—pancreatic cancer	9.61e-06	0.000141	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—pancreatic cancer	9.49e-06	0.000139	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KDR—pancreatic cancer	9.42e-06	0.000138	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.37e-06	0.000137	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CD—pancreatic cancer	9.16e-06	0.000134	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	9.07e-06	0.000133	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—pancreatic cancer	9.02e-06	0.000132	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—pancreatic cancer	8.96e-06	0.000131	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NFKBIA—pancreatic cancer	8.96e-06	0.000131	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CB—pancreatic cancer	8.88e-06	0.00013	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH1—pancreatic cancer	8.87e-06	0.00013	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—pancreatic cancer	8.8e-06	0.000129	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CB—pancreatic cancer	8.74e-06	0.000128	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—pancreatic cancer	8.68e-06	0.000127	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMS—pancreatic cancer	8.58e-06	0.000126	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGF—pancreatic cancer	8.58e-06	0.000126	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—pancreatic cancer	8.55e-06	0.000125	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—pancreatic cancer	8.4e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—pancreatic cancer	8.35e-06	0.000122	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOE—pancreatic cancer	8.25e-06	0.000121	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	8.24e-06	0.000121	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GLP1R—pancreatic cancer	8.22e-06	0.00012	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—pancreatic cancer	8.12e-06	0.000119	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—DPYD—pancreatic cancer	8.09e-06	0.000118	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—pancreatic cancer	8.04e-06	0.000118	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	7.98e-06	0.000117	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—pancreatic cancer	7.83e-06	0.000115	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—pancreatic cancer	7.75e-06	0.000114	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	7.67e-06	0.000112	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—pancreatic cancer	7.67e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	7.67e-06	0.000112	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CD—pancreatic cancer	7.63e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	7.62e-06	0.000112	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—pancreatic cancer	7.6e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—pancreatic cancer	7.55e-06	0.000111	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	7.44e-06	0.000109	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	7.41e-06	0.000109	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—pancreatic cancer	7.37e-06	0.000108	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—pancreatic cancer	7.34e-06	0.000108	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	7.34e-06	0.000108	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARG—pancreatic cancer	7.18e-06	0.000105	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	7.14e-06	0.000105	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	7.08e-06	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SRC—pancreatic cancer	7.01e-06	0.000103	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOE—pancreatic cancer	6.98e-06	0.000102	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	6.94e-06	0.000102	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	6.9e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—pancreatic cancer	6.82e-06	0.0001	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—pancreatic cancer	6.76e-06	9.9e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—pancreatic cancer	6.74e-06	9.88e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	6.73e-06	9.86e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CB—pancreatic cancer	6.65e-06	9.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.61e-06	9.68e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	6.54e-06	9.59e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SRC—pancreatic cancer	6.4e-06	9.37e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—pancreatic cancer	6.39e-06	9.36e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	6.3e-06	9.23e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—pancreatic cancer	6.28e-06	9.2e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TGFB1—pancreatic cancer	6.26e-06	9.18e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	6.23e-06	9.13e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	6.17e-06	9.04e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	6.15e-06	9.01e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—pancreatic cancer	6.14e-06	9e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—pancreatic cancer	6.11e-06	8.96e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARG—pancreatic cancer	6.08e-06	8.91e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—pancreatic cancer	5.95e-06	8.72e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CD44—pancreatic cancer	5.94e-06	8.71e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—pancreatic cancer	5.89e-06	8.64e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—pancreatic cancer	5.8e-06	8.5e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—pancreatic cancer	5.78e-06	8.47e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—pancreatic cancer	5.74e-06	8.42e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—pancreatic cancer	5.73e-06	8.4e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	5.72e-06	8.38e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	5.7e-06	8.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GCG—pancreatic cancer	5.7e-06	8.35e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—pancreatic cancer	5.65e-06	8.28e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	5.61e-06	8.21e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	5.54e-06	8.12e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—pancreatic cancer	5.41e-06	7.93e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—STK11—pancreatic cancer	5.36e-06	7.85e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	5.33e-06	7.81e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SRC—pancreatic cancer	5.33e-06	7.81e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	5.3e-06	7.76e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—pancreatic cancer	5.19e-06	7.6e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—pancreatic cancer	5.16e-06	7.55e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—pancreatic cancer	5.14e-06	7.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—pancreatic cancer	5.12e-06	7.51e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—pancreatic cancer	5.09e-06	7.46e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—pancreatic cancer	4.93e-06	7.22e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—pancreatic cancer	4.93e-06	7.22e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.86e-06	7.13e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4.83e-06	7.07e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—pancreatic cancer	4.78e-06	7.01e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—pancreatic cancer	4.77e-06	6.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TGFB1—pancreatic cancer	4.76e-06	6.98e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—pancreatic cancer	4.71e-06	6.9e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—pancreatic cancer	4.67e-06	6.84e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.61e-06	6.75e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	4.5e-06	6.59e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—pancreatic cancer	4.42e-06	6.48e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—pancreatic cancer	4.41e-06	6.46e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—pancreatic cancer	4.35e-06	6.38e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—pancreatic cancer	4.17e-06	6.11e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—pancreatic cancer	4.05e-06	5.94e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	3.97e-06	5.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—pancreatic cancer	3.92e-06	5.74e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—pancreatic cancer	3.75e-06	5.49e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOE—pancreatic cancer	3.75e-06	5.49e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	3.48e-06	5.09e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.38e-06	4.96e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—pancreatic cancer	3.31e-06	4.85e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.26e-06	4.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.97e-06	4.36e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.94e-06	4.31e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—pancreatic cancer	2.84e-06	4.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.59e-06	3.8e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.57e-06	3.76e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—pancreatic cancer	2.4e-06	3.52e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.24e-06	3.28e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.58e-06	2.31e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.29e-06	1.89e-05	CbGpPWpGaD
